209 related articles for article (PubMed ID: 11838965)
1. MHC class II proteins contain a potential binding site for the verotoxin receptor glycolipid CD77.
George T; Boyd B; Price M; Lingwood C; Maloney M
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1179-85. PubMed ID: 11838965
[TBL] [Abstract][Full Text] [Related]
2. CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to verotoxin B-subunits: implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis.
Maloney MD; Lingwood CA
J Exp Med; 1994 Jul; 180(1):191-201. PubMed ID: 7516406
[TBL] [Abstract][Full Text] [Related]
3. Comparison of adhesion mechanisms and surface protein expression in CD77-positive and CD77-negative Burkitt's lymphoma cells.
Jackson T; Van Exel C; Reagans K; Verret R; Maloney M
Cell Mol Biol (Noisy-le-grand); 2001 Nov; 47(7):1195-200. PubMed ID: 11838967
[TBL] [Abstract][Full Text] [Related]
4. CD77-dependent retrograde transport of CD19 to the nuclear membrane: functional relationship between CD77 and CD19 during germinal center B-cell apoptosis.
Khine AA; Firtel M; Lingwood CA
J Cell Physiol; 1998 Aug; 176(2):281-92. PubMed ID: 9648915
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen.
Mangeney M; Lingwood CA; Taga S; Caillou B; Tursz T; Wiels J
Cancer Res; 1993 Nov; 53(21):5314-9. PubMed ID: 8221667
[TBL] [Abstract][Full Text] [Related]
6. CD40 ligand, Bcl-2, and Bcl-xL spare group I Burkitt lymphoma cells from CD77-directed killing via Verotoxin-1 B chain but fail to protect against the holotoxin.
Gordon J; Challa A; Levens JM; Gregory CD; Williams JM; Armitage RJ; Cook JP; Roberts LM; Lord JM
Cell Death Differ; 2000 Sep; 7(9):785-94. PubMed ID: 11042673
[TBL] [Abstract][Full Text] [Related]
7. Inefficient peptide binding by cell-surface class II MHC molecules.
Sherman MA; Weber DA; Spotts EA; Moore JC; Jensen PE
Cell Immunol; 1997 Nov; 182(1):1-11. PubMed ID: 9427804
[TBL] [Abstract][Full Text] [Related]
8. Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells.
Maloney MD; Binnington-Boyd B; Lingwood CA
Glycoconj J; 1999 Dec; 16(12):821-8. PubMed ID: 11133022
[TBL] [Abstract][Full Text] [Related]
9. A site for CD4 binding in the beta 1 domain of the MHC class II protein HLA-DR1.
Brogdon J; Eckels DD; Davies C; White S; Doyle C
J Immunol; 1998 Nov; 161(10):5472-80. PubMed ID: 9820523
[TBL] [Abstract][Full Text] [Related]
10. Evidence for glycosphingolipid modification of the type 1 IFN receptor.
Ghislain J; Lingwood CA; Fish EN
J Immunol; 1994 Oct; 153(8):3655-63. PubMed ID: 7930586
[TBL] [Abstract][Full Text] [Related]
11. CD77: an antigen of germinal center B cells entering apoptosis.
Mangeney M; Richard Y; Coulaud D; Tursz T; Wiels J
Eur J Immunol; 1991 May; 21(5):1131-40. PubMed ID: 1709864
[TBL] [Abstract][Full Text] [Related]
12. Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Laufer TM; Smiley ST; Ranger A; Clements VK; Ostrand-Rosenberg S; Glimcher LH
J Immunol; 1997 Dec; 159(12):5914-20. PubMed ID: 9550388
[TBL] [Abstract][Full Text] [Related]
13. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
14. A comparison of Verotoxin B-subunit (Stx1B) and CD77 antibody to define germinal centre populations.
Bailey S; Mardell C; Wheatland L; Zola H; Macardle PJ
Cell Immunol; 2005; 236(1-2):167-70. PubMed ID: 16165112
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of the MHC class II molecules on B cells by peptide ligands.
Agrawal B; Fraga E; Kane K; Singh B
J Immunol; 1994 Feb; 152(3):965-75. PubMed ID: 8301149
[TBL] [Abstract][Full Text] [Related]
16. Staphylococcal enterotoxin H displays unique MHC class II-binding properties.
Nilsson H; Björk P; Dohlsten M; Antonsson P
J Immunol; 1999 Dec; 163(12):6686-93. PubMed ID: 10586065
[TBL] [Abstract][Full Text] [Related]
17. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
18. Contrasting cytoskeletal regulation of MHC class II peptide presentation by human B cells or dendritic cells.
Delaguillaumie A; Marin-Esteban V; Setterblad N; Leh LJ; Assier E; Gelin C; Charron D; Galy A; Mooney N
Eur J Immunol; 2008 Apr; 38(4):1096-105. PubMed ID: 18393378
[TBL] [Abstract][Full Text] [Related]
19. An essential role for HLA-DM in antigen presentation by class II major histocompatibility molecules.
Morris P; Shaman J; Attaya M; Amaya M; Goodman S; Bergman C; Monaco JJ; Mellins E
Nature; 1994 Apr; 368(6471):551-4. PubMed ID: 8139689
[TBL] [Abstract][Full Text] [Related]
20. Identification from a phage display library of peptides that bind to toxic shock syndrome toxin-1 and that inhibit its binding to major histocompatibility complex (MHC) class II molecules.
Sato A; Ida N; Fukuyama M; Miwa K; Kazami J; Nakamura H
Biochemistry; 1996 Aug; 35(32):10441-7. PubMed ID: 8756700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
